… open-label, phase-IV, follow-up study of efficacy, safety and tolerability of gefitinib in Caucasian
patients with EGFR mutation-… (plasma) for EGFR mutation analysis and assess whether …

… Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon …
Randomisation, stratified by EGFR mutation type and status of brain metastases, was done …

… Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR
mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR …

… patients with EGFR mutation-positive NSCLC. This prospective, phase II, open-label study
(… the first-line setting for Japanese patients with EGFR mutation-positive NSCLC, in order to …

… date is EGFR mutation status; recent data suggest that patients with tumours that harbour
activating mutations in EGFR (ie, exon 19 deletions or exon 21 L858R point mutations) achieve …

… Epidermal growth factor receptor (EGFR) is critical in proliferation and survival pathways,
and activating mutations are often seen in NSCLC [2]. EGFR mutations occur more frequently …

… -type EGFR or unknown EGFR mutation status had a shorter progression-free survival and
fewer objective responses. We searched PubMed using the search string “(EGFR AND lung …

… Patients were required to have documented evidence of EGFR tyrosine-kinase inhibitor
sensitising mutations. EGFR Thr790Met status and other EGFR mutations were centrally …

… However, the importance of EGFR mutations in pancreatic cancer has not been investigated
until now. The EGFR mutation profile in the Chinese population analyzed in this study can …

Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …